Fig. 6From: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapyPD-L1 expression changes contribute to resistance. Mutations in the JAK and EGFR genes result in the loss of PD-L1 expression, affecting antigen presentation. The lack of CXCL9, 10, and 11 expression prevents T cell chemotaxis in the tumor microenvironment, causing primary resistance. After PD-1 blockade, adaptive changes in various genes alter tumor cell metabolism, reduce MHC expression, and upregulate PD-L1, resulting in the inhibition of T cell activity and adaptive resistanceBack to article page